Document is current
Any future updates will be listed below
-
Authors
Hanlon, Killian S.
Kleinstiver, Benjamin P. https://orcid.org/0000-0002-5469-0655
Garcia, Sara P. https://orcid.org/0000-0003-3312-6454
Zaborowski, Mikołaj P. https://orcid.org/0000-0002-4400-6688
Volak, Adrienn
Spirig, Stefan E.
Muller, Alissa
Sousa, Alexander A.
Tsai, Shengdar Q. https://orcid.org/0000-0001-9161-3993
Bengtsson, Niclas E.
Lööv, Camilla
Ingelsson, Martin
Chamberlain, Jeffrey S.
Corey, David P.
Aryee, Martin J. https://orcid.org/0000-0002-6848-1344
Joung, J. Keith https://orcid.org/0000-0001-5630-5645
Breakefield, Xandra O.
Maguire, Casey A.
György, Bence https://orcid.org/0000-0003-0766-6246
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Center for Information Technology (R01DC017117)
- License Information
-
More Information
Article History
Received: 13 May 2019
Accepted: 11 September 2019
First Online: 30 September 2019
Competing interests
: The authors declare the following competing interests. J.K.J. has financial interests in Beam Therapeutics, Editas Medicine, Excelsior Genomics, Pairwise Plants, Poseida Therapeutics, Transposagen Biopharmaceuticals, and Verve Therapeutics (f/k/a Endcadia). J.K.J. is a member of the Board of Directors of the American Society of Gene and Cell Therapy. B.P.K. and J.K.J. are inventors on various patents and patent applications that describe gene editing and epigenetic editing technologies. S.Q.T. is a co-inventor on patents and patent applications describing gene editing technologies and methods for defining their genome-wide activities. S.Q.T. is a member of the scientific advisory board of Kromatid Inc. J.S.C and N.E.B are co-inventors on muscle-specific gene editing patents; JSC has financial interests in Solid Biosciences. C.A.M. has a financial interest in Chameleon Biosciences, Inc., a company developing an enveloped adeno-associated virus (AAV) vector platform technology for repeated dosing of systemic gene therapy. M.J.A. holds equity in Excelsior Genomics. J.K.J, C.A.M., and M.J.A.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. All other authors declare no competing interests.
